---
title: "Cerus | 10-Q: FY2025 Q2 Revenue Beats Estimate at USD 60.13 M"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251706606.md"
published_at: "2025-08-05T20:55:16.000Z"
---

# Cerus | 10-Q: FY2025 Q2 Revenue Beats Estimate at USD 60.13 M

Revenue: As of FY2025 Q2, the actual value is USD 60.13 M, beating the estimate of USD 51.8 M.

EPS: As of FY2025 Q2, the actual value is USD -0.03.

EBIT: As of FY2025 Q2, the actual value is USD -5.639 M, missing the estimate of USD -3.379 M.

### Segment Revenue

#### Product Revenue

-   **Three Months Ended June 30, 2025**: $52.445 million
-   **Three Months Ended June 30, 2024**: $45.079 million
-   **Change**: $7.366 million (16%)
-   **Six Months Ended June 30, 2025**: $95.684 million
-   **Six Months Ended June 30, 2024**: $83.444 million
-   **Change**: $12.240 million (15%)

#### Government Contract Revenue

-   **Three Months Ended June 30, 2025**: $7.684 million
-   **Three Months Ended June 30, 2024**: $5.440 million
-   **Change**: $2.244 million (41%)
-   **Six Months Ended June 30, 2025**: $13.298 million
-   **Six Months Ended June 30, 2024**: $10.470 million
-   **Change**: $2.828 million (27%)

### Operational Metrics

#### Cost of Product Revenue

-   **Three Months Ended June 30, 2025**: $23.470 million
-   **Three Months Ended June 30, 2024**: $20.413 million
-   **Change**: $3.057 million (15%)
-   **Six Months Ended June 30, 2025**: $41.285 million
-   **Six Months Ended June 30, 2024**: $37.506 million
-   **Change**: $3.779 million (10%)

#### Gross Margin on Product Sales

-   **Three Months Ended June 30, 2025**: 55%
-   **Three Months Ended June 30, 2024**: 55%
-   **Six Months Ended June 30, 2025**: 57%
-   **Six Months Ended June 30, 2024**: 55%

#### Research and Development Expenses

-   **Three Months Ended June 30, 2025**: $18.900 million
-   **Three Months Ended June 30, 2024**: $14.969 million
-   **Change**: $3.931 million (26%)
-   **Six Months Ended June 30, 2025**: $35.505 million
-   **Six Months Ended June 30, 2024**: $29.451 million
-   **Change**: $6.054 million (21%)

#### Selling, General and Administrative Expenses

-   **Three Months Ended June 30, 2025**: $21.182 million
-   **Three Months Ended June 30, 2024**: $18.973 million
-   **Change**: $2.209 million (12%)
-   **Six Months Ended June 30, 2025**: $41.468 million
-   **Six Months Ended June 30, 2024**: $38.772 million
-   **Change**: $2.696 million (7%)

#### Non-Operating Expense, Net

-   **Foreign Exchange (Loss) Gain**
    -   **Three Months Ended June 30, 2025**: - $911 thousand
    -   **Three Months Ended June 30, 2024**: - $77 thousand
    -   **Change**: - $834 thousand (1083%)
    -   **Six Months Ended June 30, 2025**: - $1.198 million
    -   **Six Months Ended June 30, 2024**: $68 thousand
    -   **Change**: - $1.266 million (1862%)
-   **Interest Expense**
    -   **Three Months Ended June 30, 2025**: - $2.150 million
    -   **Three Months Ended June 30, 2024**: - $2.330 million
    -   **Change**: $180 thousand (8%)
    -   **Six Months Ended June 30, 2025**: - $4.260 million
    -   **Six Months Ended June 30, 2024**: - $4.564 million
    -   **Change**: $304 thousand (7%)
-   **Other Income, Net**
    -   **Three Months Ended June 30, 2025**: $845 thousand
    -   **Three Months Ended June 30, 2024**: $412 thousand
    -   **Change**: $433 thousand (105%)
    -   **Six Months Ended June 30, 2025**: $1.451 million
    -   **Six Months Ended June 30, 2024**: $864 thousand
    -   **Change**: $587 thousand (68%)
-   **Total Non-Operating Expense, Net**
    -   **Three Months Ended June 30, 2025**: - $2.216 million
    -   **Three Months Ended June 30, 2024**: - $1.995 million
    -   **Change**: - $221 thousand (11%)
    -   **Six Months Ended June 30, 2025**: - $4.007 million
    -   **Six Months Ended June 30, 2024**: - $3.632 million
    -   **Change**: - $375 thousand (10%)

#### Provision for Income Taxes

-   **Three Months Ended June 30, 2025**: $76 thousand
-   **Three Months Ended June 30, 2024**: - $56 thousand
-   **Change**: $132 thousand (236%)
-   **Six Months Ended June 30, 2025**: $150 thousand
-   **Six Months Ended June 30, 2024**: $18 thousand
-   **Change**: $132 thousand (733%)

### Cash Flow

#### Net Cash (Used in) Provided by Operating Activities

-   **Six Months Ended June 30, 2025**: - $3.290 million
-   **Six Months Ended June 30, 2024**: $2.360 million

#### Net Cash Used in Investing Activities

-   **Six Months Ended June 30, 2025**: - $2.278 million
-   **Six Months Ended June 30, 2024**: - $5.661 million

#### Net Cash Provided by Financing Activities

-   **Six Months Ended June 30, 2025**: $942 thousand
-   **Six Months Ended June 30, 2024**: $4.158 million

### Future Outlook and Strategy

#### Core Business Focus

-   **Product Revenue**: Expected to increase in future periods driven by growth in global platelet business due to increased market acceptance and adoption in geographies where commercialization efforts are underway.
-   **Government Contract Revenue**: Anticipated to increase through fiscal year 2026 as multiple contracts are active and activities supporting those contracts ramp up.

#### Non-Core Business

-   **IFC Sales**: Limited until sufficient INTERCEPT Blood System for Cryoprecipitation kits are sold to blood center affiliate organizations or the number of manufacturing partners producing IFC is expanded.

#### Priority

-   **Regulatory Approvals**: Efforts to obtain regulatory approval for new LED-based illuminator and additional configurations of the platelet system in the U.S. and other geographies.
-   **Manufacturing Capacity**: Investments in capital equipment, capacity expansion, and cost reduction projects with suppliers to meet growing demand for products.

### Related Stocks

- [CERS.US - Cerus](https://longbridge.com/en/quote/CERS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Cerus 公司將參與 TD Cowen 第 46 屆年度醫療保健會議 \| CERS 股票新聞 | Cerus Corporation（納斯達克代碼：CERS）將於 2026 年 3 月 3 日上午 10:30（東部時間）在 TD Cowen 第 46 屆年度醫療保健會議上進行演講。其投資者關係頁面將提供現場直播網絡廣播，活動結束後可回放 | [Link](https://longbridge.com/en/news/276449205.md) |
| Cerus｜8-K：2025 財年營收 2.06 億美元不及預期 |  | [Link](https://longbridge.com/en/news/272274788.md) |
| Cerus 公司董事 Timothy L. Moore 將在現任期結束後卸任 | Cerus Corporation 宣佈，任期至 2026 年年度會議的董事 Timothy L. Moore 將不尋求連任 | [Link](https://longbridge.com/en/news/273663896.md) |
| Cerus 公司預計全年收入在 2.24 億至 2.28 億美元之間 | CERUS 公司預計 2025 財年收入為 2.24 億至 2.28 億美元。CERUS 公司宣佈 2025 年第四季度及全年產品收入的初步數據，並提供前景展望。CERUS 公司：2025 年第四季度產品收入總計為 5780 萬美元，與 2 | [Link](https://longbridge.com/en/news/272188095.md) |
| Stryker 公司的股票在一個強勁的交易日中表現優於競爭對手 | Stryker Corp.（SYK）的股價在強勁的交易日上漲了 2.03%，達到了 380.23 美元，表現優於競爭對手美敦力公司（Medtronic PLC，MDT），後者下跌了 0.74%。標準普爾 500 指數上漲了 0.69%，而道 | [Link](https://longbridge.com/en/news/276488101.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.